Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus
Table 2
Clinical characteristics of the patients.
Variable
All patients
Moderate-severe depressiona
No or mild depression
value
Disease duration (yrs)
10.6 (6.8)
9.6 (7.4)
11.1 (6.5)
0.19
BDI-IIb
16.7 (11.5)
30.9 (8.3)
10.3 (5.3)
<0.0001
SLEDAI-2K
5.1 (4.7)
7.7 (6.3)
3.9 (3.2)
0.002
SLICC-DI
2.4 (2.1)
2.6 (1.9)
2.3 (2.2)
0.23
Pain severityc
3.5 (2.4)
5.0 (2.2)
2.8 (2.2)
<0.001
Prednisone (%)
57.1
54.8
58.2
0.75
≥ 20 mg/day
7.1
9.7
6.0
0.51
Hydroxychloroquine (%)
68.4
71.0
67.2
0.71
Immunosuppressive (%)
41.8
35.5
44.8
0.39
Opioid use (%)
25
33.3
21.2
0.20
Antidepressants use (%)
34.4
56.7
24.2
0.002
SF-36 PCSd
38.7 (9.8)
33.7 (7.5)
41.0 (9.9)
<0.001
SF-36 MCSd
43.2 (11.3)
32.0 (8.7)
48.3 (8.3)
<0.0001
aModerate depression is defined as and severe depression as .bBeck Depression Inventory II. cPain severity (on 10 cm visual analogue scale, with 10 being the worst). dPCS is the physical component score, and MCS is the mental component score of the 36-item Short Form Health Survey (SF-36). Scores are measured on a scale of 0-100 with higher scores having better outcomes.
